Search results
Download Full Issue. Semaglutide: weighing up the benefits and risks. Joe Moody. Download PDF. More. The landscape of weight loss has changed dramatically. Semaglutide, a GLP-1 receptor analogue, was originally intended to treat diabetes (brand name Ozempic) but has found a new use resulting in rocketing popularity (Wegovy).
Semaglutide has been shown to increase energy expenditure and promote fat burning, leading to reductions in body weight and improvements in body composition. It may also have a positive impact on lipid metabolism, contributing to favorable changes in cholesterol and triglyceride levels.
11 lis 2023 · Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce...
10 lut 2021 · Our trial showed that among adults with overweight or obesity (without diabetes), once-weekly subcutaneous semaglutide plus lifestyle intervention was associated with substantial, sustained ...
13 maj 2024 · In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or...
12 paź 2024 · Semaglutide is a GLP-1 receptor agonist that provides a reduction in glycated hemoglobin and weight. The objective was to evaluate whether the use of semaglutide, in individuals with overweight...
Obesity, a multifactorial disease, is a leading cause for increased incidence of cardiovascular risk factors, including dyslipidemia, type 2 diabetes (T2D), hypertension, and sleep disorders [1]. The higher the body mass index (BMI), the greater is the risk of morbidity and mortality [2].
